Insider Traded:: CareDx Inc (CDNA) Insider Reduced $1,711,500.00 in Shares

Insider Traded:: CareDx Inc (CDNA) Insider Reduced $1,711,500.00 in Shares

CDNA stock opened at $36.86 on Thursday. CareDx Inc has a 1 year low of $5.51 and a 1 year high of $36.95.

CareDx Inc (NASDAQ:CDNA) insider Peter Maag sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $34.23, for a total value of $1,711,500.00. Following the completion of the sale, the insider now owns 458,406 shares of the company’s stock, valued at $15,691,237.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The business had revenue of $23.51 million during the quarter, compared to analysts’ expectations of $23.34 million. CareDx had a negative return on equity of 63.64% and a negative net margin of 61.06%. On average, sell-side analysts anticipate that CareDx Inc will post -0.16 EPS for the current fiscal year.

A number of research firms have recently issued reports on CDNA. HC Wainwright set a $30.00 price target on CareDx and gave the company a “hold” rating in a research report on Thursday, March 7th. Zacks Investment Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 7th. BidaskClub upgraded CareDx from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. Finally, Jefferies Financial Group began coverage on CareDx in a research report on Friday, February 15th. They issued a “buy” rating and a $35.00 price target for the company. Two analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $34.00.

Institutional investors have recently modified their holdings of the stock. MUFG Securities EMEA plc acquired a new stake in shares of CareDx in the fourth quarter valued at $6,388,000. American Century Companies Inc. acquired a new stake in shares of CareDx in the fourth quarter valued at $212,000. Geode Capital Management LLC raised its stake in shares of CareDx by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 399,668 shares of the company’s stock valued at $10,047,000 after acquiring an additional 42,944 shares in the last quarter. Millennium Management LLC raised its stake in shares of CareDx by 55.6% in the fourth quarter. Millennium Management LLC now owns 163,023 shares of the company’s stock valued at $4,098,000 after acquiring an additional 58,280 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of CareDx by 19.5% in the fourth quarter. Legal & General Group Plc now owns 6,129 shares of the company’s stock valued at $154,000 after acquiring an additional 998 shares in the last quarter. Institutional investors own 93.20% of the company’s stock.

CareDx Company Profile

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.

Further Reading: Why investors pay attention to retained earnings

Related posts

Leave a Comment